Type 2 Diabetes Connect
  • Saved
Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes - PubMed

Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38444315/

The growing use of continuous glucose monitoring (CGM) has been supported by expert consensus and clinical guidelines on glycemic management in diabetes with time in range (TIR 70-180 mg/dL) representing...

This study analyzed CGM data in 22,006 users, revealing that higher glucose variability (CV) lowers TIR/TITR, with TITR preferred for assessing near-normal glucose levels in T2D compared to T1D.

  • Saved
Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis - PubMed

Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37656235/

Our findings suggest an elevated risk of T2D in breast cancer survivors, particularly after tamoxifen therapy. Further research is needed to determine the impact of aromatase inhibitors, and chemotherapy on...

This systematic review and meta-analysis found an elevated risk of type 2 diabetes in breast cancer survivors, particularly after tamoxifen therapy, with inconclusive results for aromatase inhibitors and chemotherapy.

  • Saved
Microglial activation and polarization in type 2 diabetes-related cognitive impairment: A focused review of pathogenesis

Microglial activation and polarization in type 2 diabetes-related cognitive impairment: A focused review of pathogenesis

Source : https://pubmed.ncbi.nlm.nih.gov/39142542/

Microglia, as immune cells in the central nervous system, are closely related to cognitive impairment associated with type 2 diabetes (T2D). Preliminary explorations have investigated the relationship between T2D-related cognitive...

In summary, microglial activation and polarization in T2D contribute to cognitive impairment by mediating inflammation, neuronal apoptosis, amyloid-β deposition, and Tau phosphorylation, offering potential therapeutic targets for future interventions.

  • Saved
Type 2 diabetes in children and adolescents: Challenges for treatment and potential solutions

Type 2 diabetes in children and adolescents: Challenges for treatment and potential solutions

Source : https://pubmed.ncbi.nlm.nih.gov/39369858/

Historically perceived as a disease mainly affecting adults, the prevalence of type 2 diabetes mellitus (T2DM) among children and adolescents has been rising, mirroring the increasing rates of childhood obesity....

Youth-onset T2DM presents unique challenges due to limited therapeutic options and evidence gaps. Continued research and updated guidelines aim to optimize treatment, improve outcomes, and reduce the disease burden on youths.

  • Saved
Collaborating with Pharmacists to Improve Patient Outcomes

HCP and Pharm

In the current landscape of the American medical system, the growing complexity of patient care demands a collaborative approach where the diverse expertise of healthcare professionals converges to enhance patient outcomes. Among these collaborations, the partnership between physicians, other prescribers, and pharmacists stands out as a critical factor in delivering high-quality, comprehensive care.

For patients, this collaboration translates into better health outcomes through comprehensive treatment plans that address their needs from multiple angles. In many community pharmacy settings, a pharmacist serves as a very accessible healthcare provider—anyone can go to the pharmacy counter and ask about recommendations for over-the-counter treatments or medical advice without needing to make an appointment.

Pharmacological treatment is a cornerstone of patient care, and optimal outcomes are often contingent on the proper selection, dosing, and monitoring of medications. By collaborating with pharmacists, physicians and prescribers can leverage the complementary knowledge and experience of these medication experts to ensure that treatment goals are met. This interprofessional cooperation not only enhances the quality of care but also has the potential to reduce treatment costs, making healthcare more accessible and efficient.

Challenges and Barriers to Collaboration

Despite the clear benefits, there are significant barriers to effective collaboration between physicians and pharmacists. Legal and systemic challenges often hinder the development of a seamless partnership. Differing perspectives on roles, unclear divisions of responsibilities, and financial constraints are just a few of the obstacles that must be addressed to unlock the full potential of this collaboration.

The COVID-19 pandemic, however, has shown that these challenges can be overcome. During the pandemic, the role of pharmacists expanded significantly, often out of necessity. Pharmacists took on greater responsibilities in patient care, working closely with physicians to manage treatment plans, ensure medication safety, and provide critical support during a time of unprecedented strain on the healthcare system. Helping to provide medical consultations and vaccines during the pandemic when many providers were operating on a virtual basis helped to bridge a gap in access to care. This experience highlighted the value of pharmacist involvement and emphasized the need for ongoing teamwork between healthcare providers.

Moving Forward: The Future of Physician-Pharmacist Collaboration

The future of healthcare depends on building and nurturing multidisciplinary partnerships. By doing so, the healthcare team can improve outcomes, reduce the risk of medication-related issues, and contribute to a more efficient healthcare system.

By addressing the legal and systemic barriers, clarifying roles and responsibilities, and fostering a culture of mutual respect and communication, the medical community can create a more integrated and effective care model. As we move forward, it is crucial to continue refining and expanding this partnership, ensuring that all healthcare providers work together to achieve the best possible outcomes for their patients.

What are the key benefits of collaboration between healthcare providers, such as physicians, pharmacists, and other prescribers, in improving patient outcomes?

What are the most significant barriers to interprofessional collaboration in healthcare, and how can these be overcome?